Why the study?
Does "tailored" antiplatelet therapy improve clinical outcomes in patients with complex chronic total occlusion?
Does "tailored" antiplatelet therapy improve clinical outcomes in patients with complex chronic total occlusion?
Tailored antiplatelet therapy to overcome high platelet reactivity may improve clinical outcomes in patients with complex chronic total occlusion.
Answers are grounded in this paper and cite their sources.
Supports tailored antiplatelet therapy in complex CTO; hypothesis-generating and requires randomized confirmation before practice change.
=0.003) after multivariable adjustment. Conclusions HPR on treatment could be a modifiable prognostic marker by new antiaggregants providing a deeper platelet inhibition associated with clinical outcome improvement in complex chronic total occlusion patients. A "tailored" antiplatelet therapy, also driven by the entity of platelet inhibition, could be useful in these high risk setting patients.
No takes yet. Share an insight, caveat, or question.
Gregorio et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: